The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IVVD | +87.13% | N/A | N/A | -91% |
| S&P | +17.78% | +74.31% | +11.75% | +53% |
Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.
The clinical-stage biotech delivered positive trial results for its new COVID-19 preventative antibody treatment.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $17.21M | 24.5% |
| Gross Profit | $15.63M | 35.0% |
| Gross Margin | 90.85% | 7.1% |
| Market Cap | $684.49M | 1191.5% |
| Market Cap / Employee | $5.61M | 0.0% |
| Employees | 122 | 23.2% |
| Net Income | -$11,070.00K | 40.0% |
| EBITDA | -$12,120.00K | 31.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $226.69M | 226.9% |
| Accounts Receivable | $13.92M | 27.6% |
| Inventory | 0.3 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.18M | 0.0% |
| Short Term Debt | $1.31M | 0.8% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -25.83% | 68.9% |
| Return On Invested Capital | -106.74% | -36.2% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$15,455.00K | 58.9% |
| Operating Free Cash Flow | -$15,455.00K | 58.9% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.07 | 1.58 | 3.09 | 5.69 | 792.88% |
| Price to Sales | 1.98 | 1.86 | 3.74 | 13.04 | 523.23% |
| Price to Tangible Book Value | 1.07 | 1.58 | 3.09 | 5.69 | 792.89% |
| Enterprise Value to EBITDA | -1.57 | -3.70 | -9.90 | -38.97 | -4718.41% |
| Return on Equity | -122.7% | -120.1% | -67.9% | -34.0% | -75.51% |
| Total Debt | $894.00K | $2.97M | $2.68M | $2.49M | 91.26% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
